eczederm cream with hydrocortisone
quinoderm ltd - calamine - cream - 0.5 per cent
noskurf 100 ml lot
curatio hc. - climbazole,piroctone olamine,aminodermino - lot - 0.25w/w,0.30w/w,10;%w/w - 100 ml
noskurf 100g
curatio hc. - climabazole,piroctone olamine,aminodermin - 0.25,0.30,0.10;%w/w - 100g
xalkori
pfizer new zealand limited - crizotinib 200mg; ; - capsule - 200 mg - active: crizotinib 200mg excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).
xalkori
pfizer new zealand limited - crizotinib 250mg; ; - capsule - 250 mg - active: crizotinib 250mg excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).
xalkori capsule
pfizer canada ulc - crizotinib - capsule - 200mg - crizotinib 200mg - antineoplastic agents
xalkori capsule
pfizer canada ulc - crizotinib - capsule - 250mg - crizotinib 250mg - antineoplastic agents
lorbrena tablet
pfizer canada ulc - lorlatinib - tablet - 25mg - lorlatinib 25mg - antineoplastic agents
lorbrena tablet
pfizer canada ulc - lorlatinib - tablet - 100mg - lorlatinib 100mg - antineoplastic agents
xalkori 250mg hard capsules
pfizer (malaysia) sdn. bhd. - crizotinib -